New Ferring and Aché Laboratórios Farmacêuticos Facility Opens to Optimise Drug Delivery Using Nanotechnology
Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo, Brazil. Focused exclusively on nanotechnology research and development, the centre forms the first phase in a long term collaboration to optimise patient care through enhanced drug delivery systems and product solutions.
The Nanotechnology Innovation Laboratory Enterprise (NILE) centre and associated research programme will explore nanotechnology to advance the delivery characteristics of existing medicines, create novel devices and find new formulations for poorly soluble drugs. For example, for patients who currently receive treatment by injection, this new technology has the potential to transform their ongoing care with new oral options. Researchers will investigate how nanotechnology might improve the bioavailability, efficacy and safety profile of oral medicines, and alleviate any unwanted toxicity resulting from non-specific distribution.
Initial research projects will utilise each company’s therapeutic strengths. Ferring will provide expertise on peptides and proteins in reproductive medicine and women’s health, gastroenterology and urology, and Aché will provide knowledge on how to expedite the development of new therapeutic entities with different technical properties.
“Using nanotechnology to administer peptide and protein-based medicines orally could be a significant step forward for the ease of delivery for this important class of drugs,” said Alan Harris, Senior Vice President, R&D, Ferring Pharmaceuticals. “Ferring’s pioneering work in reproductive medicine and women’s health is devoted to providing next generation solutions that improve outcomes and better serve the needs of our patients. If we can provide patients with more convenient dosing, we will help to improve adherence and ensure that patients receive the greatest benefit from treatment.”
“In recent years, considerable investment has been made in Brazil to harness the potential of nanotechnology. Our established strength in using radical innovation to create new assets, whether synthetic, herbal, biologicals or nutraceuticals, combined with the rich source of natural compounds existing within Brazilian biodiversity, places us in a unique position to lead future cutting-edge science,” said Stephani Saverio, head of Innovation of Aché. “Nanotechnology has huge potential to address the challenges associated with today’s drug delivery systems and to optimise future care.”
The NILE centre is anticipated to be a global hub for future drug discovery and development. The inauguration ceremony brought together leading experts from the field of nanotechnology as well as dignitaries from the Ministry of Health of Brazil and government officials.
- Ends -
Nanotechnology is a branch of technology focused on understanding and controlling matter at the very smallest scales. At nanoscale, properties can be very different when compared to those with which we are familiar. Such properties mean that nanotechnology has the potential to optimise current drug delivery technologies, and offers many opportunities to create new drug delivery systems, formulations for poorly soluble drugs and novel devices. In addition to the potential advantages of enhancing systemic administration, nanoparticulate drug delivery systems can also be used for site-specific delivery, thus alleviating unwanted toxicity due to nonspecific distribution, helping to improve patient compliance and provide favourable clinical outcomes. Nanotechnology platforms will help in the development of advanced drug-delivery systems to decrease the failure rate of new active pharmaceutical ingredients (APIs), bio-therapeutic agents and vaccines caused by poor absorption, or distribution, significant drug toxicity, and rapid metabolism or excretion.
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.
Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews
About Aché Laboratórios Farmacêuticos
Aché is a 100% Brazilian company with more than 50 years of operation in the pharmaceutical market with the objective of bringing more life to the persons, wherever they are. It has three industrial sites: Guarulhos (SP), São Paulo (SP), and Londrina (PR), and participation in Melcon do Brasil, and Bionovis, a Brazilian joint venture dedicated to research and development of biotechnology medicines. It employs 4,600 people and has one of the largest demand and sales generation forces in the pharmaceutical sector in Brazil. In order to meet the needs of healthcare professionals and consumers, Aché offers a portfolio of 326 brands in 804 submissions for prescription, generic and OTC (non-prescription) drugs, and it also acts in the segments of skin cosmetics, nutraceuticals, probiotic and biological segments. Ache´s focus on innovation has been developing attractive products currently present in 20 countries of the Americas, Africa, and Asia. Ache´s innovative products are being developed for registration in the world´s most regulated markets. To know more about Aché, please visit www.ache.com.br.
Ferring Corporate Communications Team:
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
For Aché Laboratórios Farmacêuticos
CDI Corporative Communication
+55 (11) 3817-7994
+55 (11) 3817-7914
+55 (11) 3817-7925
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
SquareWell Partners Officially Launches Today to Assist Companies in Navigating the Evolving Demands of Investors25.9.2018 09:00 | Tiedote
SquareWell’s unique approach, supported by its proprietary technology, was developed out of the founding partners’ recognition of the need to optimize company-investor engagement practices and support proactive management of environmental, social and governance (ESG) risks for maximum impact. Over the last 15 years, the prominence of ESG issues has risen dramatically in the capital markets and knowing what investors prioritize and how best to communicate with them remains a challenge for companies. Furthermore, activism is no longer just an investment strategy but has become a mainstream behavior. SquareWell acknowledges this changing dynamic and facilitates progress by providing companies with year-round strategic advice regarding their investors. With SquareWell’s support, companies are better able to anticipate and identify risks and opportunities associated with long-term strategic issues, ranging from capital allocation to supply chain oversight. By analyzing existing data and lev
FRISS Survey Reveals Big Bang of Digital Transformation in Insurance is Yet to Come25.9.2018 08:30 | Tiedote
Today, FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, released the “Digital Transformation in Insurance Survey 2018”. The survey was initiated to get a better understanding of the current market state, uncovering emerging global trends in P&C insurance regarding digital transformation. Over 170 insurance professionals participated, from various countries across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005072/en/ FRISS launches Digital Transformation in Insurance Survey 2018 Digital transformation provides the insurance industry with the opportunity to use technology in order to improve efficiency, customer satisfaction and realize new strategic opportunities. These opportunities could create new services or business models and improved efficiency. Digitalization also opens doors to improve customer experience. However, digitalization can also result
AMPLEXOR a Gold Plus Sponsor of the 2018 NORDIC TechKomm in Copenhagen25.9.2018 08:03 | Tiedote
AMPLEXOR, a top-10 global language solutions provider, is a Gold Plus Sponsor and presenter at this year’s NORDIC TechKomm in Copenhagen on 26–27 September. This two-day event brings together experts from all over Europe to share best practices and present current ideas on the main conference topic, "How to make your documentation intelligent today." NORDIC TechKomm is geared toward professionals in technical communication eager to learn and share their knowledge about the latest industry trends. Attendees can expect to learn about creating effective and engaging content, ensuring documentation teams are self-sustainable, understanding the importance of AI and technical communication and more. At the 2018 NORDIC TechKomm, AMPLEXOR’s Manager of Strategic Accounts and augmented reality (AR) expert, Gilberto Picareta, will present, “Augmented Reality and Technical Authoring.” The presentation will discuss how AR is impacting technical information and communication, how to incorporate and
Veezi Signs Deal with CanalOlympia, Vivendi's Pan African Cinema Network25.9.2018 08:00 | Tiedote
Vista Group International (NZX & ASX: VGL) company Vista Entertainment Solutions (‘Vista Cinema’) and Vivendi’s CanalOlympia have signed an agreement to roll-out Vista Cinema’s Veezi across all their cinema venues. Veezi, already utilised by cinemas in 27 countries, is Vista Cinema’s SaaS cinema management solution for Independent cinemas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924006098/en/ Currently operating 9 venues across 7 countries, CanalOlympia is the leading network of cinema and live performance venues in Africa. Several additional sites are set to open in the months to come, extending the breadth of the CanalOlympia footprint. The CanalOlympia operation showcases the diversity of African culture and has helped bring cinemas back to countries currently short on entertainment choices and cultural infrastructure. The venues include the latest projection and sound technologies. They produce their own electr
Panasonic's Multi-hop HD-PLC Adopted as Smart Meter Communications System by Taiwan Power Company25.9.2018 07:27 | Tiedote
Panasonic Corporation has successfully proposed adoption to Taiwan Power Company of its HD-PLC (*1) high-speed power line communications technology as a communications system to utilize next-generation smart meters. Taiwan Power Company began accepting proposals for technology relating to communications systems in June 2017. Verification testing of the latest wireless technology and power line communications technology was held in Taipei City in September of that year. Smart meters will be introduced to approx. 260,000 households in main cities of Taiwan from December 2018. The HD-PLC technology meets the high performance criteria required, and smart meters incorporating this technology will be introduced in Taipei and other areas. Smart meters require stable communications performance to achieve detailed controls matching power demand with high-frequency data collection. The HD-PLC technology can meet these requirements and is expected to contribute to building IoT communications infr
IFF Announces Pricing of $1,500,000,000 Senior Notes Offering25.9.2018 01:25 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of $300,000,000 aggregate principal amount of its 3.400% senior notes due 2020, $400,000,000 aggregate principal amount of its 4.450% senior notes due 2028 and $800,000,000 aggregate principal amount of its 5.000% senior notes due 2048. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 26, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme